TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-dialyzed male or female patients with CKD, with a GFR of less than 30mL/min/1.73m² who have elevated serum phosphorus or who develop elevated serum phosphorus following washout from phosphorus-binding therapy.~* Patients must have written informed consent~* Negative serum pregnancy test if appropriate~* Expected to be able to comply with protocol procedures and schedule~Exclusion Criteria:~* Unstable angina pectoris~* Severe congestive heart failure~* Severe liver dysfunction~* Severe malnutrition~* Severe hyperparathyroidism~* AIDS (HIV positive subjects without AIDS are not excluded)~* Active malignancy for which the subject is receiving chemotherapy or radiation~* Subject unlikely to complete the study~* History of obstructed bowels or hypersensitivity to any of the study medications or their components~* History of swallowing disorders such as dysphagia (that would prevent the subject from taking the study drug) severe gastrointestinal motility disorders, or major GI tract surgery~* Participation in an investigational drug or device trial within 30 days of randomization~* Subjects on Vitamin D therapy~* Subjects with acute symptoms, in the last month, or current radiographic evidence of kidney stones~* Subjects who have undergone renal transplant or receiving dialysis~* Or any condition with makes patient participation not in the patients best interest

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PhosLo (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nandrolone Decanoate in the Treatment of Telomeropathies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Peripheral blood leukocytes telomeres short for age, below the first percentile of a curve based on 500 healthy individuals between 0 and 100 years, with or without a telomerase gene mutation.~AND~* One or more of the following cytopenias:~Anemia (symptoms of anemia with hemoglobin \<9.5 g/dL, or need for transfusion \> 2 units of packed red blood cells/month for at least two months, or absolute reticulocytes count \<60.000/μL).~Thrombocytopenia (platelets counts \<30.000/μL or \<50.000/μL associated with bleeding, or megakaryocytes reduction in the bone marrow).~Neutropenia (absolute neutrophil counts \<1.000/μL).~OR~* Idiopathic pulmonary fibrosis diagnosed according to the American Thoracic Society (ATS) criteria.~Exclusion Criteria:~* Terminal disease or liver disease, renal, cardiac, neurological, infectious or concomitant metabolic state whose gravity prevents the ability of the patient to tolerate the treatment protocol, or probable death within 30 days.~* People with cancer who are undergoing chemotherapy.~* Pregnancy, or desire to not prevent pregnancy in childbearing age.~* Aplastic Anemia patients with indication for bone marrow transplantation and matched donor.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Nandrolone Decanoate (Type: EXPERIMENTAL): Nandrolone Decanoate intramuscularly administered, every two weeks, 5 mg/kg/dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety, Efficacy and Pharmacokinetics of CA-008 (Vocacapsaicin)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled elective Total Knee Arthroplasty (TKA) under spinal anesthesia~* Aged 18-80 years old~* ASA physical class 1, 2, or 3~* BMI \</= 42 kg/m2~* Generally healthy~Exclusion Criteria:~* Concurrent condition requiring analgesic treatment during study period~* Opioid tolerant~* Known allergy to capsaicin or other study medication~* Use of prohibited medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CA-008 36 mg (Type: ACTIVE_COMPARATOR): Single administration (0.3 mg/mL concentration)
- CA-008 60 mg (Type: ACTIVE_COMPARATOR): Single administration (0.5 mg/mL concentration)
- CA-008 90 mg (Type: ACTIVE_COMPARATOR): Single administration (0.75 mg/mL concentration)
- Placebo (Type: PLACEBO_COMPARATOR): Single administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* One of the following diagnoses:~  * Newly diagnosed B-cell non-Hodgkin's lymphoma in Revised European-American Lymphoma (REAL) categories II 9, 10, and 11, i.e.:~    * Diffuse large cell~   * Burkitt's~   * High-grade B-cell, Burkitt's-like~ * L3 leukemia with greater than 5% blasts in bone marrow~* No anaplastic large cell Ki1-positive lymphomas~* Immunophenotype and Murphy stage required prior to randomization~PATIENT CHARACTERISTICS:~Age:~* Over 6 months to under 21 years~  * Maximum age 18 years in France and the United Kingdom~Other:~* No congenital immunodeficiency~* No prior organ transplantation~* No prior malignancy~* Not HIV positive~* Available for at least 36 months of follow-up~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Steroids initiated no more than 72 hours prior to entry allowed~  * Bone marrow and cerebrospinal fluid examination required prior to steroids~Radiotherapy:~* Emergency radiotherapy initiated no more than 72 hours prior to entry allowed~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): All resected stage I and Abdominal stage II only. All Group A patients will be treated with two cycles of COPAD and will be followed in a confirmatory study of the current result of nearly 100% cure rate.
- Group B (Type: ACTIVE_COMPARATOR): Non resected stage I \& II, stage III \& st IV (CNS - ve, BM \< 25%). Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimise the risk of this. Prior to any chemotherapy being administered intravenous hydration fluids should be given run at a rate of 3000 mls/m2/day. Alkalinisation may be necessary Pay close attention to fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumour lysis persists.
- Group C (Type: ACTIVE_COMPARATOR): Bone marrow \> 25% but CNS negative Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimize the risk of this. Intravenous hydration fluids should be given prior to chemotherapy. Alkalinisation may be necessary. Monitor fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumor lysis persists

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. MSM (cisgender male)~2. Self-reported use of non-alcohol substances of abuse in past 6 months~3. Currently taking PrEP~4. Has qualifying laboratory tests (Cr, hepatitis B immunization, STI testing and syphilis)~5. Age 18 or older~Exclusion Criteria:~1. Does not speak English~2. HIV positive~3. Identifies as transgender~4. Estimated creatinine clearance \<60ml/min~5. Active hepatitis B treatment~6. Does not own a smartphone~7. Taking proton pump inhibitors~8. History of Crohn's disease or ulcerative colitis~9. History of bowel surgery, gastric bypass, bowel stricture~10. History of GI malignancy or radiation to abdomen~11. Unable/unwilling to ingest digital pill

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Digital Pills (Type: EXPERIMENTAL): Digital Pills containing Truvada ingested once daily as PrEP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients between 18 - 75 years~* Recipients of single-organ renal primary allograft or second renal transplants (provided that the previous graft was not lost from acute rejection within the first year) from living or cadaver donors~* Patients who provide written informed consent.~Exclusion Criteria:~* PRA \> 20% within 6 months prior to enrollment~* Cold ischemia time \> 30 hours~* Previous treatment with daclizumab~* History of malignancy (except localized skin cancer)~* Active peptic ulcer disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Effectiveness and Safety of Radiesse (+) to Improve the Contour of Jawline by Adding Volume to the Jawline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has right and left jawline ratings of 2 or 3 (moderate or severe) on the Merz Jawline Assessment Scale (MJAS).~2. Has the same MJAS score on both jawlines (that is, jawlines are symmetrical).~3. Is greater than or equal to (\>=) 22 and less than or equal to (\<=) 65 years of age.~Exclusion Criteria:~1. Ever been treated with fat injections or permanent fillers (example, silicone, polymethylmethacrylate (PMMA)) in the lower face and/or jawline area or plans to receive such treatments during participation in the study.~2. Been treated with semi-permanent dermal fillers (example, poly L-lactic acid) in the lower face and/or jawline area in the past 5 years or plans to receive such treatments during participation in the study.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment with Radiesse (+) (Type: EXPERIMENTAL): None
- Control/Delayed Treatment with Radiesse (+) (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic genotype 1 hepatitis C virus (HCV) infection~* Plasma HCV RNA of more than 10,000 IU/mL at screening~* Patients in Cohort 1 must be null responders to PegIFN/ribavirin with at least 1 documented previous course of PegIFN/ribavirin therapy for at least 12 consecutive weeks~* Patients in Cohort 2 must be null responders to PegIFN/ribavirin with at least 1 documented previous course of PegIFN/ribavirin therapy for at least 12 consecutive weeks and could also be HCV treatment-naive, meaning never received treatment with any approved or investigational drug for the treatment of HCV~* Null responders patients in Cohort 1 and Cohort 2 must meet the defined criterion for a null responder, defined as on-treatment less than 2 log10 IU/mL reduction in HCV RNA from baseline at Week 12 of the most recent PegIFN/ribavirin therapy~* Patient must have had a liver biopsy within 3 years before screening (or between screening and baseline visit) or patient must have had a liver biopsy at any time in the past which showed Metavir F3 or F4 fibrosis~* Must agree to use 2 forms of effective contraception throughout the study (male and female)~Exclusion Criteria:~* Has evidence of hepatic decompensation~* Has any liver disease of non-HCV etiology~* Has an infection/co-infection with non-genotype 1 HCV~* Has a co-infection with Human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or HIV-2) (positive HIV-1 or HIV-2 antibody test at screening)~* Has a co-infection with hepatitis B virus (hepatitis B surface antigen \[HBsAg\] positive)~* Has a history of malignancy within 5 years of the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): 30 patients will receive TMC435 (150 mg once a day) plus PSI-7977(GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 24 weeks and followed by a 24-week follow-up phase.
- Arm 2 (Type: EXPERIMENTAL): 15 patients wiil receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 24 weeks of and followed by a 24-week follow-up phase.
- Arm 3 (Type: EXPERIMENTAL): 30 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 12 weeks and followed by a 36-week follow-up phase.
- Arm 4 (Type: EXPERIMENTAL): 15 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 12 weeks and followed by a 36-week follow-up phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are eligible and able to participate in the study, and who give written informed consent before any assessment is performed.~* Men or women 18 years and older.~* Patients with Stage 2 systolic hypertension; defined as having a MSSBP ≥160 mmHg and \<180 mmHg at Visit 5 (randomization).~Exclusion Criteria:~* Use of aliskiren or participation in a clinical trial that had aliskiren as treatment within 30 days of Visit 1.~* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\>5 mIU/ml).~* Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels \>40 mIU/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy OR are using one or more of the following acceptable methods of contraception: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception (implantable, patch, oral), and double-barrier methods. Reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation.~* Severe hypertension (an office cuff MSDBP ≥110 mmHg and/or MSSBP ≥180 mmHg).~* Refractory hypertension, defined as unresponsive to triple drug therapy at the maximum dose of each drug, one of which must be a diuretic, and not at blood pressure goal (140/90 mmHg).~* Patients treated with more than 3 antihypertensive medications (each component of a combination drug counts individually).~* History or evidence of a secondary form of hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Valsartan/aliskiren (Type: EXPERIMENTAL): None
- Valsartan (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be healthy boys or girls, 11-17 years of age~* Must be a virgin with no intention of becoming sexually active during the study period~* Must have been properly vaccinated against diphtheria, tetanus and pertussis~Exclusion Criteria:~* Must not have received a vaccine against diphtheria, tetanus and pertussis in the past 5 years~* Must not have received any prior human papillomavirus (HPV) vaccine or meningococcal vaccine

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Concomitant Administration
- Group 2 (Type: EXPERIMENTAL): Non-concomitant administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Steroid Reduces Systemic Inflammation in COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* stable symptoms of COPD in the previous 3 months before study entry; forced expiratory volume in one second (FEV1) after bronchodilation with 400 mcg salbutamol that was 25 to 90% of predicted, a change of less than 20% of predicted FEV1, 30 minutes following bronchodilation, and a FEV1/forced vital capacity (FVC) of less than 75%; history of at least 10 pack-years of smoking or prolonged exposure (\>10 years) to noxious gases (e.g. diesel fumes).~Exclusion Criteria:~* active malignancy; unable to follow instructions; patients taking any anti-inflammatory medications

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have postmenopausal status.~* Adenocarcinoma of the breast.~* Breast tumor ≥1 centimeter (cm) in diameter, HR+, HER2-.~* Neoadjuvant endocrine monotherapy is deemed to be a suitable therapy.~* Primary breast cancer that is suitable for baseline core biopsy.~* Have adequate organ function.~Exclusion Criteria:~* Bilateral invasive breast cancer.~* Metastatic breast cancer (local spread to axillary lymph nodes is permitted).~* Inflammatory breast cancer.~* Prior systemic therapy or radiotherapy for invasive or non-invasive breast cancer in the same breast as currently being treated.~* Prior radiotherapy to the ipsilateral chest wall for any malignancy.~* Prior anti-estrogen therapy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abemaciclib + Anastrozole (Type: EXPERIMENTAL): Abemaciclib (150 milligrams \[mg\]) was given orally every 12 hours (Q12H) plus anastrozole (1 mg) orally once daily (QD) for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks.
- Abemaciclib (Type: EXPERIMENTAL): Abemaciclib (150 mg) was given orally Q12H for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks.
- Anastrozole (Type: ACTIVE_COMPARATOR): Anastrozole (1 mg) is given orally QD for 2 weeks.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Loperamide was given as a prophylaxis for the first 2 weeks of the combination treatment and then at physician discretion. Total treatment duration was 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete